Dimensional Fund Advisors LP Sells 41,658 Shares of Labcorp Holdings Inc. $LH

Dimensional Fund Advisors LP lowered its position in Labcorp Holdings Inc. (NYSE:LH) by 3.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,246,556 shares of the medical research company’s stock after selling 41,658 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Labcorp were worth $357,794,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in LH. Vanguard Group Inc. grew its position in Labcorp by 1.6% during the second quarter. Vanguard Group Inc. now owns 9,879,225 shares of the medical research company’s stock worth $2,593,395,000 after buying an additional 156,717 shares in the last quarter. State Street Corp boosted its position in shares of Labcorp by 0.9% during the 2nd quarter. State Street Corp now owns 3,863,039 shares of the medical research company’s stock valued at $1,014,086,000 after acquiring an additional 36,003 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Labcorp by 20.0% during the third quarter. Victory Capital Management Inc. now owns 2,637,350 shares of the medical research company’s stock worth $756,878,000 after purchasing an additional 440,224 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Labcorp by 2.2% in the second quarter. Geode Capital Management LLC now owns 2,113,460 shares of the medical research company’s stock worth $552,445,000 after purchasing an additional 44,630 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Labcorp by 3.5% in the second quarter. JPMorgan Chase & Co. now owns 1,303,307 shares of the medical research company’s stock valued at $342,131,000 after purchasing an additional 43,661 shares in the last quarter. Institutional investors own 95.94% of the company’s stock.

Insider Activity

In other Labcorp news, EVP Jonathan C. Meltzer sold 87 shares of the business’s stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $290.42, for a total value of $25,266.54. Following the transaction, the executive vice president owned 2,782 shares in the company, valued at approximately $807,948.44. The trade was a 3.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brian J. Caveney sold 1,500 shares of the company’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $286.31, for a total transaction of $429,465.00. Following the transaction, the executive vice president directly owned 30,107 shares of the company’s stock, valued at approximately $8,619,935.17. This trade represents a 4.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 16,113 shares of company stock valued at $4,547,450 in the last three months. Corporate insiders own 0.84% of the company’s stock.

Labcorp Stock Performance

NYSE LH opened at $275.80 on Friday. The company has a 50-day simple moving average of $270.68 and a two-hundred day simple moving average of $270.30. Labcorp Holdings Inc. has a 12-month low of $209.38 and a 12-month high of $293.72. The firm has a market cap of $22.73 billion, a price-to-earnings ratio of 26.37, a PEG ratio of 1.92 and a beta of 1.01. The company has a quick ratio of 1.23, a current ratio of 1.42 and a debt-to-equity ratio of 0.60.

Labcorp (NYSE:LH) last released its earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share for the quarter, beating analysts’ consensus estimates of $3.95 by $0.12. The company had revenue of $3.52 billion during the quarter, compared to analyst estimates of $3.56 billion. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.Labcorp’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.45 EPS. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. On average, equities analysts forecast that Labcorp Holdings Inc. will post 16.01 EPS for the current year.

Labcorp Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 12th. Stockholders of record on Friday, February 27th will be issued a $0.72 dividend. The ex-dividend date is Friday, February 27th. This represents a $2.88 annualized dividend and a dividend yield of 1.0%. Labcorp’s dividend payout ratio (DPR) is currently 27.53%.

Wall Street Analyst Weigh In

A number of equities analysts have commented on LH shares. JPMorgan Chase & Co. boosted their price target on shares of Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Weiss Ratings upgraded shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, February 10th. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Piper Sandler lifted their price target on Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 24th. Finally, Robert W. Baird increased their price objective on Labcorp from $313.00 to $326.00 and gave the company an “outperform” rating in a research report on Wednesday, February 18th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Labcorp presently has a consensus rating of “Moderate Buy” and an average target price of $304.82.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.